Details of the Drug Combination

General Information of Drug Combination (ID: DCVC7J4)

Drug Combination Name

Bifemelane Nitisinone

Indication

Disease Entry	Status	REF
DD2	Investigative	[1]

Component Drugs

Bifemelane DMU73F0

Nitisinone DMVS9WQ

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: DD2

Zero Interaction Potency (ZIP) Score: 0.284

Bliss Independence Score: 7.383

Loewe Additivity Score: 0.57

LHighest Single Agent (HSA) Score: 2.599

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Bifemelane

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Terminated	[2]

Bifemelane Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Monoamine oxidase type A (MAO-A)	TT3WG5C	AOFA_HUMAN	Modulator	[2]
------------------------------------------------------------------------------------

Indication(s) of Nitisinone

Disease Entry	ICD 11	Status	REF
Hereditary tyrosinemia type 1	5C50.11	Approved	[3]

Nitisinone Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Hydroxyphenylpyruvate dioxygenase (HPD)	TT8DSFC	HPPD_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6834).
4	Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36.